Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02469285
Other study ID # KarniMari-HY
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date September 2014
Est. completion date November 2014

Study information

Verified date May 2022
Source University of Helsinki
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

High consumption of red meat is related to cardiovascular diseases. Red meat containing more unsaturated fat than normal red meat may have a beneficial impact on plasma lipid and fatty acid profile in humans. Furthermore, consumption of red meat and especially processed red meat is considered harmful to colon health. However, consumption of fruit and berries rich in antioxidants and flavonoids may provide protection when red meat is consumed. The study aims to answer whether the fatty acid profile of pork when modified towards more unsaturated fat will affect plasma fatty acids and lipids in adult volunteers. The effects of pork with a modified fatty acid content is compared with conventional pork with lower unsaturated fat content. Fatty acid composition of pork is modified by altering the composition of animal feed. The other arm of the study investigates the effects of consuming berries together with red meat on gut metabolism. The study focuses on how berries affect the formation of fecal compounds known to be related to high red meat consumption, such as N-nitroso compounds.


Recruitment information / eligibility

Status Completed
Enrollment 65
Est. completion date November 2014
Est. primary completion date November 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years to 68 Years
Eligibility Inclusion Criteria: - diet includes meat Exclusion Criteria: - high consumption of fish (4 times per week) - use of fish oil/ omega-3 oil capsules one month before the intervention - hypercholesterolemia - vegetarian, vegan

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Modified pork
Pork with modified fatty acid composition
Pork
Pork with normal fat composition
Pork and berries
Pork with normal fat composition and Finnish berries

Locations

Country Name City State
Finland Division of Nutrition, University of Helsinki Helsinki

Sponsors (1)

Lead Sponsor Collaborator
University of Helsinki

Country where clinical trial is conducted

Finland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in plasma fatty acids as a measure of dietary fatty acid modification 4 weeks
Primary Change in fecal nitroso compounds as a measure of increased (processed) red meat consumption Measured as apparent total nitroso compounds (ATNC) 4 weeks
Primary Genotoxicity testing of human fecal water in 3D cell culture Fecal water is isolated from fecal samples collected before and after the intervention period from arms B and C. The samples are tested for markers of genotoxicity in 3D cell culture. 4 weeks
Secondary Changes in plasma lipids as a measure of dietary modification Concentrations of and changes in total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides are measured before and after the intervention period 4 weeks
Secondary Concentration of polyphenolics in fecal water as a measure of consumption of berries The polyphenol content of the fecal water is assessed from arms B and C 4 weeks
Secondary Change in hemoglobin as a measure of dietary modification 4 weeks
Secondary Change in blood pressure as a measure of dietary modofcation Blood pressure is measured before and after the study period. 4 weeks
Secondary Weight development during the study period The subjects are weighed before and after the study and their weight is monitored weekly during the study 4 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT04515303 - Digital Intervention Participation in DASH
Completed NCT04056208 - Pistachios Blood Sugar Control, Heart and Gut Health Phase 2
Recruiting NCT04417387 - The Genetics and Vascular Health Check Study (GENVASC) Aims to Help Determine Whether Gathering Genetic Information Can Improve the Prediction of Risk of Coronary Artery Disease (CAD)
Not yet recruiting NCT06211361 - Cardiac Rehabilitation Program in Patients With Cardiovascular Disease N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT04514445 - The BRAVE Study- The Identification of Genetic Variants Associated With Bicuspid Aortic Valve Using a Combination of Case-control and Family-based Approaches.
Enrolling by invitation NCT04253054 - Chinese Multi-provincial Cohort Study-Beijing Project
Completed NCT03273972 - INvestigating the Lowest Threshold of Vascular bENefits From LDL Lowering With a PCSK9 InhibiTor in healthY Volunteers N/A
Completed NCT03680638 - The Effect of Antioxidants on Skin Blood Flow During Local Heating Phase 1
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Completed NCT04083872 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers(Fasting) Phase 1
Completed NCT04083846 - Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of High-dose CKD-385 in Healthy Volunteers(Fed) Phase 1
Completed NCT03693365 - Fluid Responsiveness Tested by the Effective Pulmonary Blood Flow During a Positive End-expiratory Trial
Completed NCT03619148 - The Incidence of Respiratory Symptoms Associated With the Use of HFNO N/A
Completed NCT03466333 - Postnatal Enalapril to Improve Cardiovascular fUnction Following Preterm Pre-eclampsia Phase 2
Completed NCT04082585 - Total Health Improvement Program Research Project
Completed NCT05132998 - Impact of a Comprehensive Cardiac Rehabilitation Program Framework Among High Cardiovascular Risk Cancer Survivors N/A
Completed NCT05067114 - Solutions for Atrial Fibrillation Edvocacy (SAFE)